APA (7th ed.) Citation

Gencer, D., Hofheinz, R., Al-Batran, S., Dada, R., Hun͏̈erlitur͏̈koglu, A., Gonnermann, M., . . . Kellermann, L. (2013). Metastatic esophagogastric adenocarcinoma: Trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. Journal of cancer research and clinical oncology, 139(2), . https://doi.org/10.1007/s00432-012-1335-7

Chicago Style (17th ed.) Citation

Gencer, Deniz, et al. "Metastatic Esophagogastric Adenocarcinoma: Trends in First-line Treatment and Predictive Factors for the Implementation of HER2 Testing in Clinical Practice During the First Year After Trastuzumab Market Approval." Journal of Cancer Research and Clinical Oncology 139, no. 2 (2013). https://doi.org/10.1007/s00432-012-1335-7.

MLA (9th ed.) Citation

Gencer, Deniz, et al. "Metastatic Esophagogastric Adenocarcinoma: Trends in First-line Treatment and Predictive Factors for the Implementation of HER2 Testing in Clinical Practice During the First Year After Trastuzumab Market Approval." Journal of Cancer Research and Clinical Oncology, vol. 139, no. 2, 2013, https://doi.org/10.1007/s00432-012-1335-7.